Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses

  • Y. Gomi
  • T. Imagawa
  • M. Takahashi
  • K. Yamanishi
Conference paper


When nucleotide sequences of Oka vaccine and its parental viruses of varicella-zoster virus (VZV) were compared in 5 open reading frames (ORFs) including glycoprotein C (gC) and 4 immediate-early genes, mutations were detected only in gene 62 which is one of the immediate-early genes. Compared with its parental virus, the vaccine virus contained 15 nucleotide substitutions. With the differentiation method using the simplified restriction-enzyme fragment length polymorphism analysis by Nae I and Bss HII, which was established based on the sequence analysis data in this study, the Oka vaccine virus could be distinguished from its parental virus. Studies of the regulatory activities of the ORF62 gene product (1E62) in a transient assay indicate the 1E62 of the parental virus had a stronger transactivational activity than that of the vaccine virus against immediate-early, early and late gene promoters. These data suggest that gene 62 might have an important role for attenuation of VZV. This is the first report in which many substitutions of nucleotides in gene 62 of Oka vaccine virus was found, compared with that of Oka parental virus.


Herpes Zoster Parental Virus Transactivational Activity Effector Plasmid Cognate Promoter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baudoux L, Defechereux P, Schoonbroodt S, Merville MP, Rentier B, Piette J (1995) Mutational analysis of varicella-zoster virus major immediate-early protein 1E62. Nucleic Acids Res 23: 1341–1349PubMedCrossRefGoogle Scholar
  2. 2.
    Davison AJ, Scott JE (1986) The complete DNA sequence of varicella-zoster virus. J Gen Virol 67: 1759–1816CrossRefGoogle Scholar
  3. 3.
    Defechereux P, Melen L, Baudoux L, Merville-Louis MP, Rentier B, Piette J (1993) Characterization of the regulatory functions of varicella-zoster virus open reading frame 4 gene product. J Virol 67: 4379–4385PubMedGoogle Scholar
  4. 4.
    Gelb LD, Dohner DE, Gershon AA, Steinberg SP, Waner JL, Takahashi M, Dennehy PH, Brown AE (1987) Molecular epidemiology of live, attenuated varicella virus vaccine in children with leukemia and in normal adults. J Infect Dis 155: 633–640PubMedCrossRefGoogle Scholar
  5. 5.
    Inchauspe G, Nagpal S, Ostrove JM (1989) Mapping of two varicella-zoster virus-encoded genes that activate the expression of viral early and late genes. Virol 173: 700–709CrossRefGoogle Scholar
  6. 6.
    Jackers P, Defechereux P, Baudoux L, Lambert C, Massaer M, Merville-Louis MP, Rentier B, Piette J (1992) Characterization of regulatory functions of the varicella-zoster virus gene 63-encoded protein. J Virol 66: 3899–3903PubMedGoogle Scholar
  7. 7.
    Kinchington PR, Ling P, Pensiero M, Gershon A, Hay J, Ruyechan WT (1990) A possible role for glycoprotein gpV in the pathogenesis of varicella-zoster virus. Adv Exp Med Biol 278: 83–91PubMedCrossRefGoogle Scholar
  8. 8.
    Kinchington PR, Hougland K, Arvin AM, Ruyechan WT, Hay J (1992) The varicellazoster virus immediate-early protein IE62 is a major component of virus particles. J Virol 66: 359–366PubMedGoogle Scholar
  9. 9.
    LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg SP, Silverstein S (1992) Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 66: 1016–1020PubMedGoogle Scholar
  10. 10.
    Ling P, Kinchington PR, Ruyechan WT, Hay J (1991) A detailed analysis of transcripts mapping to varicella zoster virus gene 14 (glycoprotein V). Virology 184: 625–635PubMedCrossRefGoogle Scholar
  11. 11.
    Ling P, Kinchington PR, Sadeghi-Zadeh M, Ruyechan WT, Hay J (1992) Transcription from varicella-zoster virus gene 67 (glycoprotein IV). J Virol 66: 3690–3698PubMedGoogle Scholar
  12. 12.
    Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM (1998) Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 72: 965–974PubMedGoogle Scholar
  13. 13.
    Mori C, Takahara R, Toriyama T, Nagai T, Takahashi M, Yamanishi K (1998) Identification of the Oka strain of the live attenuated varicella vaccine from other clinical isolates by molecular epidemiologic analysis. J Infect Dis 178: 35–38PubMedCrossRefGoogle Scholar
  14. 14.
    Moriuchi M, Moriuchi H, Straus S, Cohen JI (1994) Varicella-Zoster virus (VZV) virionassociated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virol 200: 297–300CrossRefGoogle Scholar
  15. 15.
    Perera LP, Mosca JD, Ruyechan WT, Hay J (1992) Regulation of varicella-zoster virus gene expression in human T lymphocytes. J Virol 66: 5298–5304PubMedGoogle Scholar
  16. 16.
    Schoonbroodt S, Piette J, Baudoux L, Defechereux P, Rentier B, Merville MP (1996) Enhancement of varicella-zoster virus infection in cell lines expressing ORF4- or ORF62- encoded proteins. J Med Virol 49: 264–273PubMedCrossRefGoogle Scholar
  17. 17.
    Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2: 1288–1290PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Y. Gomi
    • 1
  • T. Imagawa
    • 1
  • M. Takahashi
    • 2
  • K. Yamanishi
    • 3
  1. 1.Kanonji InstituteThe Research Foundation for Microbial Diseases of Osaka UniversityKanonji, KagawaJapan
  2. 2.The Research Foundation for Microbial Diseases of Osaka UniversitySuita, OsakaJapan
  3. 3.Department of MicrobiologyOsaka University Medical SchoolSuita, OsakaJapan

Personalised recommendations